Inclusion Criteria:
  -  Age: older than 18 years
  -  WHO (ECOG) performance status 0-2
  -  Histological proven HNSCC
  -  HPV negative tumors or HPV positive tumors
  -  Stage III, IVA or IVB HNSCC according to UICC and AJCC guidelines
  -  Tumor classified as irresectable or patient inoperable or patient refused surgery
  -  Tumor extension and localization suitable for radiochemotherapy with curative intent
  -  Simultaneous standard chemotherapy with cisplatin applicable (no contra-indications)
  -  Dental examination and -treatment before start of therapy
  -  For women with childbearing potential and men in reproductive ages adequate contraception.
  -  Ability of subject to understand character and individual consequences of the clinical trial
  -  Written informed consent (must be available before enrolment in the trial)
Exclusion Criteria:
  -  Refusal of the patients to take part in the trial
  -  Presence of distant metastases (UICC stage IVC)
  -  Previous radiotherapy in the head and neck region
  -  Second malignancy that is likely to require treatment during the trial intervention or follow-up period or that, in the opinion of the physician, has a considerable risk of recurrence or metastases within the follow-up period
  -  Serious disease or medical condition with life expectancy of less than one year
  -  Participation in competing interventional trial on cancer treatment
  -  Patients who are not suitable for radiochemotherapy
  -  Pregnant or lactating women
  -  Patients not able to understand the character and individual consequences of the trial
  -  Nasopharyngeal Carcinomas